Article
Pharmacology & Pharmacy
Victor Moreno, Richard Greil, Jeffrey Yachnin, Margarita Majem, Martin Wermke, Hendrik-Tobias Arkenau, Jean-Rene Basque, Prasanna Kumar Nidamarthy, Shruti Kapoor, Xiaoming Cui, Monica Giovannini
Summary: The study showed that capmatinib, at doses of 300 and 400 mg twice daily with food, exhibited favorable pharmacokinetic characteristics and good safety profile in patients with MET-dysregulated advanced solid tumors. Dose escalation to 400 mg twice daily did not result in dose-limiting toxicity.
CLINICAL THERAPEUTICS
(2021)
Article
Oncology
Yang Luo, Ying Cheng, Chunjiao Wu, Hui Ye, Naihan Chen, Fan Zhang, Hua Wei, Binghe Xu
Summary: This phase 1 study examined the pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. The results demonstrated that the pharmacokinetic profile of talazoparib in Chinese patients was similar to that in Western populations, and the treatment was well-tolerated.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Rujiao Liu, Wenhua Li, Yanchun Meng, Shuiping Gao, Jian Zhang, Xichun Hu
Summary: Pucotenlimab demonstrated antitumor effects in patients with advanced solid tumors, with acceptable safety profile and no reached maximum tolerated dose, suggesting potential for further development.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
David Bussing, Sharad Sharma, Zhe Li, Lyndsey F. Meyer, Dhaval K. Shah
Summary: Our study revealed a linear relationship between ADC payload and antigen expression levels in vivo, emphasizing the importance of understanding the complex physiology of tumors for predicting ADC performance within the tumor. Antigen expression screening is crucial for maximizing the therapeutic benefit of targeted therapies like ADCs.
Article
Oncology
Toshio Shimizu, Kazuhiko Nakagawa, Hidetoshi Hayashi, Tsutomu Iwasa, Hisato Kawakami, Satomi Watanabe, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Keiichi Kikuchi, Kenichiro Akaike, Shiho Takeda, Masayuki Takeda
Summary: This study aimed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of orally-administered bendamustine in Japanese patients with advanced solid tumors. The study found that orally-administered bendamustine at a dose of 75 mg/m(2) once daily for 7 days every 3 weeks showed acceptable hematologic recovery and demonstrated antitumor effects in some patients. The pharmacokinetics of orally-administered bendamustine were generally dose-dependent with a relatively large inter-individual variability.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Alon Kahana, Shelby P. Unsworth, Christopher A. Andrews, May P. Chan, Scott C. Bresler, Christopher K. Bichakjian, Alison B. Durham, Hakan Demirci, Victor M. Elner, Christine C. Nelson, Denise S. Kim, Shannon S. Joseph, Paul L. Swiecicki, Frances P. Worden
Summary: The study tested the hypothesis that the use of the hedgehog inhibitor vismodegib could improve vision-related outcomes in patients with orbital and extensive periocular BCC, successfully preserving globe and visual function. Results showed that most patients maintained stable or improved visual assessment scores after treatment with vismodegib, with a majority experiencing complete tumor regression.
Article
Oncology
Yoshito Komatsu, Tsuneo Shimokawa, Kohei Akiyoshi, Masato Karayama, Akihiko Shimomura, Yasuyuki Kawamoto, Satoshi Yuki, Yuichi Tambo, Kazuo Kasahara
Summary: This study compared the bioavailability of two formulations of pimitespib, evaluated the effect of food on one formulation, and assessed the safety and efficacy of multiple doses of pimitespib in patients with solid tumors. The results showed that the two formulations were not bioequivalent, with the systemic exposure of one formulation being about 20% lower than the other. Additionally, a high-fat/calorie meal increased the relative pharmacokinetics and bioavailability of a single dose of the formulation.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Pharmacology & Pharmacy
Chandrasekar Durairaj, Jayeta Chakrabarti, Cristiano Ferrario, Holger W. Hirte, Sunil Babu, Sarina A. Piha-Paul, Anna Plotka, Justin Hoffman, Haihong Shi, Diane D. Wang
Summary: This study investigated the pharmacokinetic profile of talazoparib in patients with varying degrees of renal impairment and demonstrated an increase in exposure with worsening renal function. Current dosing recommendations for mild and moderate renal impairment were confirmed, while a lower starting dose should be considered for patients with severe renal impairment.
CLINICAL PHARMACOKINETICS
(2021)
Article
Chemistry, Analytical
Fen Yang, Jun Zhou, Yunhai Bo, Han Yin, Xiao Hong Liu, Jian Li
Summary: A simple and reliable UHPLC-MS/MS method was developed for the determination of TQ-B3203 in human plasma, with good stability and accuracy. The method was successfully applied to a pharmacokinetic study in cancer patients.
JOURNAL OF SEPARATION SCIENCE
(2021)
Article
Pharmacology & Pharmacy
Marit A. C. Vermunt, Vincent A. de Weger, Julie M. Janssen, Marta Lopez-Yurda, Marianne Keessen, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Serena Marchetti
Summary: This study evaluated the impact of consuming food before taking ModraDoc006/r on the pharmacokinetics of docetaxel and ritonavir. While there was a slight increase in docetaxel exposure and decrease in ritonavir C-max with a high-fat meal, the overall conclusion was that the combined ModraDoc006 and ritonavir treatment may be slightly affected by concurrent intake of a high-fat meal. It is likely that a light meal will not significantly influence the systemic exposure to docetaxel.
Article
Oncology
Jason J. Luke, Fabrice Barlesi, Ki Chung, Anthony W. Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, Vivek Subbiah, Frank Tsai, Steven Kao, Philippe A. Cassier, Mustafa Khasraw, Hedy L. Kindler, Hua Fang, Frances Fan, Kathryn Allaire, Maulik Patel, Shiming Ye, Debra T. Chao, William R. Henner, Joel S. Hayflick, Michael A. McDevitt, Lawrence Fong
Summary: The study found that ABBV-428 monotherapy demonstrated dose-proportional pharmacokinetics and an acceptable safety profile, particularly in relation to toxicities associated with CD40 agonism. This indicates that utilizing a tumor-targeted, bispecific antibody can enhance the safety of CD40 agonism as a therapeutic approach.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Eleonora Nicolo, Paolo Tarantino, Oriana D'Ecclesiis, Gabriele Antonarelli, Luca Boscolo Bielo, Antonio Marra, Sara Gandini, Edoardo Crimini, Federica Giugliano, Paola Zagami, Chiara Corti, Dario Trapani, Stefania Morganti, Carmen Criscitiello, Marzia Locatelli, Carmen Belli, Angela Esposito, Ida Minchella, Massimo Cristofanilli, Sara M. Tolaney, Giuseppe Curigliano
Summary: This study evaluates the correlation between baseline burden of disease measured by CT scan and outcomes in patients with advanced solid tumors receiving experimental targeted therapies. The results show that higher baseline tumor size is associated with worse survival outcomes, especially in patients receiving biomarker-matched targeted therapies.
Article
Medicine, General & Internal
Chien-Chang Kao, Ching-Liang Ho, Ming-Hsin Yang, Yi-Ta Tsai, Shu-Yu Liu, Ping-Ying Chang, Yi-Ying Wu, Jia-Hong Chen, Ren-Hua Yehn, Ming-Shen Dai, Yeu-Chin Chen, Guang-Huan Sun, Tai-Lung Cha
Summary: The co-administration therapy of GW5074 and sorafenib showed favorable safety profile and anti-tumor activity in patients with refractory advanced solid cancers. However, the solubility of GW5074 was not satisfactory.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Judy Wang, Patricia Martin-Romano, Philippe Cassier, Melissa Johnson, Eric Haura, Laurie Lenox, Yue Guo, Nibedita Bandyopadhyay, Michael Russell, Elizabeth Shearin, Josh Lauring, Laetitia Dahan
Summary: This study investigated the use of the oral inhibitor JNJ-74699157, targeting the KRAS G12C mutation, in advanced cancer patients. Dose escalation led to dose-limiting toxicities of increased blood CPK and no significant clinical benefit was observed. Further enrollment was stopped due to these findings.
Article
Oncology
Hannah E. Olsen, Kevin X. Liu, A. Lindsay Frazier, Allison F. O'Neill, Katherine A. Janeway, Steven G. Dubois, David S. Shulman
Summary: This retrospective cohort study analyzed pediatric cancer patients who received serial multitargeted tyrosine kinase inhibitor (mTKI) therapy between 2007 and 2020. The study found that the response rate to mTKI rechallenge was low, but patients who received the first mTKI for more than 4 months had longer stable disease with the second mTKI. Some patients had a response or stable disease on the second mTKI despite progression on the first mTKI. Though toxicity was common, only a minority of patients discontinued the second mTKI due to toxicity.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Natalie R. Young, Christian Soneru, Jing Liu, Tatyana A. Grushko, Ashley Hardeman, Olufunmilayo I. Olopade, Anke Baum, Flavio Solca, Ezra E. W. Cohen
Article
Oncology
Rodney J. Taylor, Vassiliki Saloura, Ajay Jain, Olga Goloubeva, Stuart Wong, Shari Kronsberg, Madhavi Nagilla, Lorna Silpino, Jonas de Souza, Tanguy Seiwert, Everett Vokes, Victoria Villaflor, Ezra E. W. Cohen
CANCER IMMUNOLOGY RESEARCH
(2015)
Article
Oncology
V. M. Villaflor, J. M. Melotek, T. G. Karrison, R. J. Brisson, E. A. Blair, L. Portugal, J. A. De Souza, D. T. Ginat, K. M. Stenson, A. Langerman, M. Kocherginsky, M. T. Spiotto, N. Hannigan, T. Y. Seiwert, E. E. W. Cohen, E. E. Vokes, D. J. Haraf
ANNALS OF ONCOLOGY
(2016)
Article
Oncology
P. M. Clement, T. Gauler, J. P. Machiels, R. I. Haddad, J. Fayette, L. F. Licitra, M. Tahara, E. E. W. Cohen, D. Cupissol, J. J. Grau, J. Guigay, F. Caponigro, G. de Castro, L. de Souza Viana, U. Keilholz, J. M. del Campo, X. J. Cong, E. Ehrnrooth, J. B. Vermorken
ANNALS OF ONCOLOGY
(2016)
Review
Oncology
Ezra E. W. Cohen, Samuel J. LaMonte, Nicole L. Erb, Kerry L. Beckman, Nader Sadeghi, Katherine A. Hutcheson, Michael D. Stubblefield, Dennis M. Abbott, Penelope S. Fisher, Kevin D. Stein, Gary H. Lyman, Mandi L. Pratt-Chapman
CA-A CANCER JOURNAL FOR CLINICIANS
(2016)
Article
Oncology
Isabel J. Boero, Anthony J. Paravati, Beibei Xu, Ezra E. W. Cohen, Loren K. Mell, Quynh-Thu Le, James D. Murphy
JOURNAL OF CLINICAL ONCOLOGY
(2016)
Article
Oncology
Kristen Pettit, Wendy Stock, Roland B. Walter
LEUKEMIA & LYMPHOMA
(2016)
Article
Multidisciplinary Sciences
Megan M. Kaneda, Karen S. Messer, Natacha Ralainirina, Hongying Li, Christopher J. Leem, Sara Gorjestani, Gyunghwi Woo, Abraham V. Nguyen, Camila C. Figueiredo, Philippe Foubert, Michael C. Schmid, Melissa Pink, David G. Winkler, Matthew Rausch, Vito J. Palombella, Jeffery Kutok, Karen McGovern, Kelly A. Frazer, Xuefeng Wu, Michael Karin, Roman Sasik, Ezra E. W. Cohen, Judith A. Varner
Article
Oncology
Kosuke Yamaguchi, Ramiro Iglesias-Bartolome, Zhiyong Wang, Juan Luis Callejas-Valera, Panomwat Amornphimoltham, Alfredo A. Molinolo, Ezra E. Cohen, Joseph A. Califano, Scott M. Lippman, Ji Luo, J. Silvio Gutkind
Article
Oncology
William N. William, Vassiliki Papadimitrakopoulou, J. Jack Lee, Li Mao, Ezra E. W. Cohen, Heather Y. Lin, Ann M. Gillenwater, Jack W. Martin, Mark W. Lingen, Jay O. Boyle, Dong M. Shin, Nadarajah Vigneswaran, Nancy Shinn, John V. Heymach, Ignacio I. Wistuba, Ximing Tang, Edward S. Kim, Pierre Saintigny, Elizabeth A. Blair, Timothy Meiller, J. Silvio Gutkind, Jeffrey Myers, Adel El-Naggar, Scott M. Lippman
Article
Oncology
Beibei Xu, Isabel J. Boero, Lindsay Hwang, Quynh-Thu Le, Vitali Moiseenko, Parag R. Sanghvi, Ezra E. W. Cohen, Loren K. Mell, James D. Murphy
Article
Oncology
Michaela K. Keck, Zhixiang Zuo, Arun Khattri, Thomas P. Stricker, Christopher D. Brown, Matin Imanguli, Damian Rieke, Katharina Endhardt, Petra Fang, Johannes Braegelmann, Rebecca DeBoer, Mohamed El-Dinali, Serdal Aktolga, Zhengdeng Lei, Patrick Tan, Steve G. Rozen, Ravi Salgia, Ralph R. Weichselbaum, Mark W. Lingen, Michael D. Story, K. Kian Ang, Ezra E. W. Cohen, Kevin P. White, Everett E. Vokes, Tanguy Y. Seiwert
CLINICAL CANCER RESEARCH
(2015)
Article
Oncology
Tanguy Y. Seiwert, Zhixiang Zuo, Michaela K. Keck, Arun Khattri, Chandra S. Pedamallu, Thomas Stricker, Christopher Brown, Trevor J. Pugh, Petar Stojanov, Juok Cho, Michael S. Lawrence, Gad Getz, Johannes Braegelmann, Rebecca DeBoer, Ralph R. Weichselbaum, Alexander Langerman, Louis Portugal, Elizabeth Blair, Kerstin Stenson, Mark W. Lingen, Ezra E. W. Cohen, Everett E. Vokes, Kevin P. White, Peter S. Hammerman
CLINICAL CANCER RESEARCH
(2015)
Article
Health Care Sciences & Services
Katy Gallop, Cicely Kerr, Stacey Simmons, Bryan McIver, Ezra E. W. Cohen
QUALITY OF LIFE RESEARCH
(2015)
Article
Otorhinolaryngology
Maggie A. Kuhn, M. Boyd Gillespie, Stacey L. Ishman, Lisa E. Ishii, Rebecca Brody, Ezra Cohen, Shumon I. Dhar, Kate Hutcheson, Gina Jefferson, Felicia Johnson, Anais Rameau, David Sher, Heather Starmer, Madeleine Strohl, Karen Ulmer, Vilija Vaitaitis, Sultana Begum, Misheelt Batjargal, Nui Dhepyasuwan
Summary: This study aimed to develop an expert consensus statement on the management of dysphagia in head and neck cancer patients. Through systematic review of the literature, 48 consensus statements were developed, addressing risk factors, screening, evaluation, prevention, intervention, and surveillance.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
(2023)